CCNA1 gene as a potential diagnostic marker in papillary thyroid cancer

Autor(es)

da Silva, Raissa Monteiro ^[1] ; Santos, Joyce Nascimento ^[1] ; Uno, Miyuki ^[2] ; Chammas, Roger ^[2] ; Vamondes Kulcsar, Marco Aurelio ^[3] ; Sant'Anna, Luciana Barros ^[4] ; Canevari, Renata de Azevedo ^[1]

Afiliação do(s) autor(es)

^[1] Univ Vale Paraiba, Inst Pesquisa & Desenvolvimento, Lab Biol Mol Canc, UNIVAP, Ave Shishima Hifumi 2911, BR-12244000 Sao Jose Dos Campos, SP - Brazil

^[2] Univ Sao Paulo FMUSP, Ctr Invest Translac Oncol, Inst Canc Estado Sao Paulo ICESP, Dept Radiol & Oncol, Fac Med, Ave Dr Arnaldo 251, BR-01246000 Sao Paulo, SP - Brazil

^[3] Inst Canc Estado Sao Paulo ICESP, Serv Cirurgia Cabeca & Pescoco, Av Doutor Arnaldo 251, BR-01246000 Sao Paulo, SP - Brazil

^[4] Univ Vale Paraiba, Inst Pesquisa & Desenvolvimento, Lab Histol & Terapia Regenerat, UNIVAP, Ave Shishima Hifumi 2911, BR-12244000 Sao Jose Dos Campos, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: ACTA HISTOCHEMICA; v. 122, n. 8 DEC 2020.
• Citações Web of Science: 0

Resumo

The malignancy that most affects the endocrine system is thyroid neoplasm, with an increasing incidence over the years. The most prevalent histological type of the carcinomas that affect the thyroid gland is papillary carcinoma with a prevalence of 80 % worldwide. The current diagnostic methodology may present inconclusive results, emphasizing the need for new effective and sensitive techniques to aid the diagnosis. For this, it is necessary to understand molecular and protein mechanisms in the identification of diagnostic and predictive markers in the lesions. The Cyclin A1 protein, encoded by the CCNA1 gene, is an important cell cycle regulator, belonging to the MAPK/ERK signaling pathway directly involved with thyroid cancer. The aim of this study was to evaluate the CCNA1 gene and Cyclin A1 protein expression in papillary thyroid carcinoma, follicular thyroid carcinoma, and benign thyroid lesions, by real time quantitative PCR and immunohistochemistry analysis, respectively, to verify their roles as potential diagnostic and predictive markers to future applications in the clinical routine. Overexpression of CCNA1 gene was observed in the papillary carcinoma group compared to the normal group (P = 0.0023), benign lesions (P = 0.0011), colloid goiter (P = 0.0124), and follicular carcinoma (P = 0.0063). No differential expression was observed in the papillary primary tumor group from negative lymph nodes compared with the one from positive lymph nodes (P = 0.3818). Although an increased expression of Cyclin A1 was observed in the PTC group compared to the other one in the IHC analysis, no significant difference was observed (Fisher's exact Test). A Cyclin A1 overexpression was detected with weak to mid-moderate immunoreactivity in the benign group (k = 0.56), (score 1.5); mid-moderate to moderate in the goiter group (k = 0.58); weak in the FTC group (k = 0.33); and mid-moderate to moderate in the PTC group (k = 0.48). Due to the small sample size in the IHC analysis and to the fact that not all RNA is translated into protein, the diagnostic potential of Cyclin A1 could not be assessed. However, these findings highlight the potential of the CCNA1 gene as a diagnostic marker for papillary thyroid carcinoma. (AU)

• Processo FAPESP: 09/18440-1 - Desenvolvimento de marcadores moleculares relacionados à resistência celular após terapia fotodinâmica em carcinomas mamários
• Beneficiário: Renata de Azevedo Canevari
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 13/14464-9 - Caracterização molecular e bioquímica de lesões da tireóide para diagnóstico clínico
• Beneficiário: Renata de Azevedo Canevari
• Modalidade de apoio: Auxílio à Pesquisa - Regular